Pancreatic Cancer Research

ResearcherOsaka International Cancer InstituteActive in the last 2 years

Shinichiro Hasegawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8117-8350; OpenAlex author ID A5074232226, A5102795256, A5108883130. Sources: OpenAlex.

Their work

Papers
22
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 4 papers · 2025: 1 paper · 2026: 7 papers

Papers 22

  1. Preoperative Gemcitabine/Nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative… Co-author DOI 10.1002/ags3.70191↗
  2. Relationship Between Radiographic and Pathological Portal Vein-Superior Mesenteric Vein Involvement in Neoadjuvant Treatment for Pancreatic Cancer: A Comparati… Co-author DOI 10.1002/wjs.70395↗
  3. A soft tissue mass around the arteries after pancreatectomy: the association with local recurrence and the impact of neoadjuvant radiotherapy in pancreatic duc… Co-author DOI 10.1007/s00595-026-03341-w↗
  4. Clinical significance of non-invasive in vitro drug sensitivity profiling using pancreatic cancer organoids derived from saline flushes collected during routin… Co-author DOI 10.1007/s12094-025-04111-9↗
  5. Prognostic significance of neoadjuvant gemcitabine and S-1 chemotherapy with or without concurrent radiation in patients with resectable and borderline resecta… Co-author DOI 10.1016/j.surg.2025.109864↗
  6. Exosomal microRNA-4800-3p in portal vein blood promotes liver metastasis in pancreatic cancer by targeting PLAA. Co-author DOI 10.1038/s41598-026-48779-7↗
  7. Circ72309 modulates gemcitabine metabolism and gemcitabine sensitivity in pancreatic cancer: Serum Circ72309 levels as a potential predictor of treatment respo… Co-author DOI 10.3892/ijo.2026.5849↗
  8. Surgical outcomes of histopathological stage I pancreatic cancer with special reference to oncological differences between pStage I and ypStage I cases. Co-author DOI 10.1016/j.suronc.2025.102225↗
  9. Prognostic impact of aberrant right hepatic artery involvement in patients with pancreatic cancer: A multicenter retrospective cohort study. Co-author DOI 10.1002/jso.27792↗
  10. A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radical surgery in resectable and borderline resectable pancreatic ca… Co-author DOI 10.1016/j.surg.2024.06.049↗
  11. The preliminary analysis of lymphatic flow around the connective tissues surrounding SMA and SpA elucidates patients' oncological condition in borderline-resec… Co-author DOI 10.1186/s12893-024-02398-z↗
  12. ASO Author Reflections: A Novel Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers Enhances Predictive Significance in Patients with a Modest Radi… Co-author DOI 10.1245/s10434-024-15021-5↗
  13. DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Co-author DOI 10.1186/s12885-023-10512-2↗
  14. Establishment of organoids using residual samples from saline flushes during endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic ca… Co-author DOI 10.1055/a-1713-3404↗
  15. Difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvan… Co-author DOI 10.1002/ags3.12418↗
  16. Clinical implications of the serum CA19-9 level in "biological borderline resectability" and "biological downstaging" in the setting of preoperative chemoradia… Co-author DOI 10.1016/j.pan.2020.05.020↗
  17. Pathological complete response (pCR) with or without the residual intraductal carcinoma component following preoperative treatment for pancreatic cancer: Revis… Co-author DOI 10.1002/ags3.12288↗
  18. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1038/srep42339↗
  19. A crucial epithelial to mesenchymal transition regulator, Sox4/Ezh2 axis is closely related to the clinical outcome in pancreatic cancer patients. Co-author DOI 10.3892/ijo.2015.3258↗
  20. Pre-treatment neutrophil to lymphocyte ratio as a predictive marker for pathological response to preoperative chemoradiotherapy in pancreatic cancer. Co-author DOI 10.3892/ol.2015.4057↗
  21. Cyclin G2: A novel independent prognostic marker in pancreatic cancer. Co-author DOI 10.3892/ol.2015.3667↗
  22. MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer. Co-author DOI 10.1038/bjc.2014.454↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hirofumi Akita · 14 shared papers, 2019–2026 · strength 2.87
  2. Daisaku Yamada · 13 shared papers, 2017–2026 · strength 2.35
  3. Yuichiro Doki · 14 shared papers, 2014–2026 · strength 2.21
  4. Yoshito Tomimaru · 14 shared papers, 2014–2026 · strength 2.21
  5. Hidenori Takahashi · 12 shared papers, 2019–2026 · strength 2.08
  6. Hidetoshi Eguchi · 11 shared papers, 2014–2026 · strength 1.46
  7. Yoshifumi Iwagami · 7 shared papers, 2021–2026 · strength 1.42
  8. Tadafumi Asaoka · 8 shared papers, 2016–2026 · strength 1.28
  9. Yosuke Mukai · 5 shared papers, 2023–2026 · strength 0.96
  10. Kazuki Sasaki · 4 shared papers, 2024–2026 · strength 0.81
  11. Naoko Sekiguchi · 3 shared papers, 2025–2026 · strength 0.72
  12. Kunihito Gotoh · 4 shared papers, 2017–2026 · strength 0.63
  13. Masahiko Kubo · 3 shared papers, 2024–2026 · strength 0.62
  14. Masato Sakon · 4 shared papers, 2020–2024 · strength 0.54
  15. Hidetoshi Eguchi · 2 shared papers, 2025–2026 · strength 0.51
  16. Satoru Miyahara · 2 shared papers, 2024–2026 · strength 0.42
  17. Kenji Ikezawa · 2 shared papers, 2022–2026 · strength 0.38
  18. Ryoji Takada · 2 shared papers, 2022–2026 · strength 0.38
  19. Hisataka Ogawa · 2 shared papers, 2022–2026 · strength 0.38
  20. Yugo Kai · 2 shared papers, 2022–2026 · strength 0.38
  21. Tomoya Ekawa · 2 shared papers, 2022–2026 · strength 0.38
  22. Shigenori Nagata · 2 shared papers, 2022–2026 · strength 0.38
  23. Hideaki Tahara · 2 shared papers, 2022–2026 · strength 0.38
  24. Kazuyoshi Ohkawa · 2 shared papers, 2022–2026 · strength 0.38
  25. Yutaka Takeda · 2 shared papers, 2017–2026 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.